• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study shows lower mortality from induction of labor at 41 weeks

Bioengineer by Bioengineer
November 21, 2019
in Health
Reading Time: 4 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Photo by Malin Arnesson


Inducing labor after 41 instead of 42 full weeks’ pregnancy appears to be safer in terms of perinatal survival, new Swedish research shows. The current study is expected to provide a key piece of evidence for upcoming decisions in maternity care.

In Sweden, the risk of a baby dying before, during or shortly after birth (“perinatal death”) is generally very low. However, a progressive rise in risk from a low level is known to take place after the 40th week, for as long as the pregnancy continues.

The purpose of the current study, published in The BMJ, was to investigate these risks and compare outcomes of induction after 41 and 42 full gestational weeks. To date, there have been some doubts regarding the best means of protecting mother and baby alike.

The study comprised 2,760 women admitted to 14 maternity hospitals in Sweden in the years 2016-2018. None had an underlying disease, they were all expecting one baby only (a “singleton birth”), and their pregnancies had lasted for 41 full weeks at the time of inclusion in the study.

Half of the women in the study (1,381 individuals) were randomly assigned to receive induction at 41 full weeks. In this group 86% underwent induction, while labor started without assistance among the others.

In the second group (1,379 women), induction was planned to take place at 42 full weeks. This is routine management at most birth centers in Sweden for pregnancies not involving complications. In practice, 33% of this group of women needed induction to start labor.

Regarding the women’s state of health after childbirth, there was no difference between the groups. The proportions of cesareans and instrumental deliveries (using a suction cup, and/or forceps) were also approximately equal. According to the criterion that combines perinatal morbidity and death, just over 30 babies were affected in each group.

On the other hand, specifically in terms of the deaths, a significant difference was found. In the group where labor was induced after 41 full gestational weeks, there were no deaths. In the other group, in which spontaneous labor was waited for (“expectant management”) and induction carried out at 42 weeks, six cases of perinatal death were registered: five of the babies were stillborn and one died immediately after birth.

Because of these deaths, the study was discontinued early. In the event, the number of women included was therefore 2,760 instead of the planned 10,000. Sweden’s birth centers were informed of the outcome and, after external review of the material, the study — headed by Sahlgrenska Academy at the University of Gothenburg, and Sahlgrenska University Hospital — is now being published.

Ulla-Britt Wennerholm, senior clinical physician and associate professor of obstetrics and gynecology at Sahlgrenska Academy, University of Gothenburg, is one of the two lead authors.

“The study shows that there’s a difference in the number of deaths when induction is done at 41 and 42 weeks. All the same, we should be a bit cautious in interpreting the results, since we had to break of the study early. The outcome might have been slightly different in a larger study, but the pattern would probably have been the same,” she says.

Henrik Hagberg, senior clinical physician and professor of obstetrics and gynecology at Sahlgrenska Academy, University of Gothenburg, is one of the senior authors.

“If you put together all the data from our own and previous studies, you can see that mortality is lower if labor is induced at 41 weeks than if we wait and start labor at 42 weeks. The state of current knowledge is now being reviewed, and it’s not unreasonable to expect women to be offered induction at 41 weeks,” he says.

“What we’ve also shown in this study is that there don’t seem to be any medical disadvantages of induction at 41 weeks instead of 42. Many people predicted that it would increase the risk of cesarean and instrumental deliveries, but neither rate increased,” Henrik Hagberg states.

###

Titel: Induction of labour at 41 weeks versus expectant management and induction of labour at 42 weeks (SWEdish Post-term Induction Study, SWEPIS): multicentre, open label, randomised, superiority trial; https://www.bmj.com/content/bmj/367/bmj.l6131.full.pdf

Contacts:

University of Gothenburg, Sahlgrenska Academy and University Hospital:

Henrik Hagberg, senior author, professor, senior clinical physician, +46 705 505 773; [email protected]

Ulla-Britt Wennerholm, first author, associate professor, senior clinical physician,

+46 702 932 959; [email protected]

Karolinska Institutet and University Hospital:

Sissel Saltvedt, first author, M.D., senior clinical physician, +46 727 115 161;

[email protected]

Media Contact
Ulla-Britt Wennerholm
[email protected]
46-702-932-959

Original Source

https://sahlgrenska.gu.se/english/research/news-events/news-article/?languageId=100001&contentId=1655656&disableRedirect=true&returnUrl=http%3A%2F%2Fsahlgrenska.gu.se%2Fforskning%2Faktuellt%2Fnyhet%2F%2Fstudie-visar-pa-lagre-dodlighet-vid-igangsattni

Related Journal Article

http://dx.doi.org/10.1136/bmj.l6131

Tags: Death/DyingGynecologyHealth Care Systems/ServicesMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Sex Differences in Alcohol’s Impact on Brain Dopamine

September 6, 2025

Fecal Transplants: New Hope for Alzheimer’s Treatment

September 6, 2025

CheckMate 77T: Nivolumab Preserves Quality of Life and Mitigates Symptom Worsening in Resectable NSCLC

September 6, 2025

miR-BART19-3p Boosts EBV-Associated Gastric Cancer Growth

September 6, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    54 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Phase II Study Finds Iza-Bren Plus Osimertinib Achieves 100% Response Rate in EGFR-Mutated NSCLC

Novel Antibody-Drug Conjugate Demonstrates Promising Efficacy in EGFR-Mutated NSCLC Patients

COMPEL Study Finds Adding Chemotherapy to Osimertinib After Progression Enhances Progression-Free Survival in EGFR-Mutated NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.